Amgen Raises 2026 Outlook as Q3 Revenue Grows 8% to $10.4 Billion
Amgen (AMGN) reported Q3 2026 revenue of $10.365B, up 8% YoY, and raised full-year revenue and EPS guidance. GAAP net income rose 19% to $3.864B. Product sales increased 8% to $9.883B, driven by volume growth. The company expects 2026 revenue of $38.9B-$39.7B and non-GAAP EPS of $22.90-$23.70. Free cash flow declined to $3.654B.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised 2026 revenue and non-GAAP EPS ranges, supported by volume growth and GAAP margin expansion, but offset by ongoing biosimilar erosion (Prolia, XGEVA) and a decline in free cash flow.
Market read
Guidance raise and margin improvement are likely supportive for AMGN, but biosimilar erosion and weaker free cash flow add caution for the next few quarters.
What to watch
Investors may underweight the near-term cash drag from working-capital timing and the ramp in late-stage studies (MariTide Phase 3 additions), which could pressure FCF even if EPS holds up.
Background
Amgen reported Q3 2026 results and updated full-year revenue and EPS guidance, while detailing product-level trends amid biosimilar competition and pipeline progress.
Ticker impact
Amgen raised its 2026 revenue outlook to $38.9B-$39.7B and non-GAAP EPS to $22.90-$23.70 after Q3 revenue rose 8% to $10.365B.
Shares likely face net upward pressure as the market prices in stronger full-year earnings power, partially offset by concerns about ongoing denosumab biosimilar share loss and weaker free cash flow.
The article contains explicit raised full-year revenue and EPS ranges plus detailed drivers (volume growth, margin expansion) alongside clear negatives (Prolia and XGEVA declines, free cash flow down on working-capital and higher capex).
Market effects
Reinforces the biotech large-cap narrative that volume growth and cost discipline can offset biosimilar pressure, but cash generation may lag due to working-capital timing and higher R&D/capex.
Primarily US large-cap healthcare sentiment; could modestly influence peers’ read-across on biosimilar impact and margin resilience.
Limited direct global spillover beyond multinational pharma expectations for 2026 growth and biosimilar competitive dynamics.
Counterpoint
The guidance raise may be more about accounting and mix than durable demand, given free cash flow fell and denosumab-related declines were material.
Key entities
- companyAmgen
Raised 2026 revenue and non-GAAP EPS outlook after Q3 revenue growth; highlighted biosimilar-driven declines in denosumab products and rising R&D/capex.
- pipeline_assetABP 206
Investigational biosimilar to OPDIVO with FDA BLA accepted for review, expecting agency action by end of 2026.
- pipeline_programMariTide
Plans to initiate two additional Phase 3 studies in Type 2 diabetes in Q4 2026, expanding late-stage obesity and cardiometabolic efforts.
